Key result
Review details the pathophysiology of rhabdomyolysis linked to statin and fibrate therapy.
Why the study?
The pathophysiology of renal injury in rhabdomyolysis-related acute renal failure is not fully understood, including factors beyond muscle damage that contribute to tubular necrosis.
Answers are grounded in this paper and cite their sources.
Rhabdomyolysis is a common clinical and laboratory syndrome, resulting from skeletal muscle injury, that leads to the release of potentially toxic muscle cell contents, specifically myoglobin, into the plasma (1)(2). Rhabdomyolysis can be induced by many different mechanisms and has been implicated as a major cause of acute renal failure. However, when correct treatment is provided, it is usually reversible. Acute tubular necrosis after rhabdomyolysis does not always appear to parallel the degree of muscle damage, but it may be related to other factors that potentiate the effects of myoglobinuria, such as hypotension, acidosis, and volume depletion. The pathophysiology of the renal injury is not fully understood, but it probably includes a combination of hypoperfusion/ischemia, iron tubular cytotoxicity, and cast formation potentially leading to proximal tubular necrosis and acute renal failure. The combination of fibrates plus 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) is an effective and generally well-tolerated treatment for high-risk patients with mixed dyslipidemias, and side effects, mainly hepatic and muscular disorders, are rare. However, when they do occur, muscular damage may be severe, leading to rhabdomyolysis (3)(4).
No takes yet. Share an insight, caveat, or question.
Bairaktari et al. (2002) studied Rhabdomyolysis. The abstract discusses the pathophysiology of rhabdomyolysis and its association with statin and fibrate therapy, but reports no quantitative study results.
Synapse has enriched 10 related papers. Consider them for comparative context: